EMA starts review of Cidara's candidiasis therapy rezafungin

The EU regulator has started its review of Cidara Therapeutics' once-weekly antifungal rezafungin, setting up a decision next year as a new option for serious, invasive infections caused by

Cidara and Mundipharma prep filings for antifungal rezafungi...

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in t

New deals extend Mundipharma biosimilar reach

Mundipharma, Grünenthal accused of kickbacks in Italy

Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor to promote use of the drugs.

Mundipharma's Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.